ArticleNature communications2026
Ultrasensitive detection of lung inflammation in male mice using immuno-magnetic particle imaging.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timely and sensitive detection of inflammatory and infectious lung diseases remains a major clinical challenge. Current diagnostic approaches often identify pathology only at advanced stages, leaving gaps in acute triage, fibrotic activity assessment, transplant rejection monitoring and inflammation follow-up. Magnetic Particle Imaging (MPI) offers a sensitive, background-free, whole-body imaging modality without ionizing radiation. Here, we present immuno-Magnetic Particle Imaging (immuno-MPI) using micron-sized iron oxide particles targeted to VCAM-1, a key marker of endothelial inflammation. In three lung inflammation models in male mice, MPIO@αVCAM-1 generates high-contrast images within 3 minutes following intravenous injection at 1 mg/kg, with rapid accumulation at the inflamed endothelium and fast clearance of unbound particles. Predominantly confined to the vasculature, these particles selectively target VCAM-1 and discriminate inflamed from healthy lungs at doses as low as 0.18 mg/kg (7.5 µg iron). Specificity for VCAM-1 is confirmed by the absence of signal using control antibodies (MPIO@IgG) and competitive blocking with free αVCAM-1 antibodies. Overall, immuno-MPI provides a non-invasive approach that avoids ionizing radiation and supports pulmonary inflammation monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.